Pharmaceuticals, Biotechnology and Life Sciences
Assay Builds on Alzheon’s Research to Detect and Quantify Soluble Oligomers, and Enhances Phase 2 and Phase 3 Alzheimer’s Studies with Oral ALZ-801 Quantitative Assay to Monitor Alzheimer’s Disease Onset...
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today announced the initiation of a rolling submission of...
A Phase 2/3 trial to evaluate a new fully-human polyclonal antibody therapeutic targeted to SARS-CoV-2, called SAB-185, has begun enrolling non-hospitalized people with mild or moderate cases of COVID-19. The trial, ACTIV-2, is sponsored by the National Institute of Allergy...
Researchers from the National Institutes of Health have identified and tested a drug combination that exploits a weakness in small...
An international team of scientists has found evidence that SARS-CoV-2, the virus that causes COVID-19, infects cells in the mouth....
LA JOLLA, Calif., May 05, 2021 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market…
Montrouge, France, May 5, 2021 DBV Technologies Announces Filing of its First Form 10-Q for the First Quarter of 2021…
Not for distribution by US newswire or in United States NESS-ZIONA, Israel, May 05, 2021 (GLOBE NEWSWIRE) — VAXIL BIO…
CHARLESTON, S.C., May 05, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a…
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES NOR…
LOS ANGELES–(BUSINESS WIRE)–AIDS Healthcare Foundation (AHF), the world’s largest provider of HIV/AIDS care globally, applauded today President Biden’s historic decision…
– ZYNLONTA is the first and only CD19-targeted ADC approved as a single-agent treatment for adult patients with r/r DLBCL…
Investigational New Drug (IND) Application Submitted for Phase 2/3 AIS Study Plan to Initiate Phase 2/3 AIS Trial in Summer…
Shareholders URGED to Vote the BLUE proxy by 9:00 a.m. on May 12, 2021 TORONTO–(BUSINESS WIRE)–$HUGE–FSD Pharma Inc. (the “Company”)…
VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the…
